GlassScriptPhysician profile
Elizabeth Mclain
NPI 1811407653
$6,519.73
in general payments reported to CMS, 2019-2025
37 companies · $1,864 in 2025
The $1,864 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $773 · 2022: $1,271 · 2023: $1,253 · 2024: $1,359 · 2025: $1,864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,475.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,425.07 | 2021-2025 | |
| Novo Nordisk INC | $846.07 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $387.49 | 2023-2025 | |
| Lilly USA, LLC | $387.31 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Avion Pharmaceuticals | $340.20 | 2021-2022 | |
| Evofem Biosciences, INC. | $307.03 | 2021-2022 | |
| Aspira Women'S Health INC | $247.05 | 2022 | |
| Amgen INC. | $241.90 | 2024-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $220.32 | 2023-2025 | Farxiga, Breztri |
| Idorsia Pharmaceuticals US INC | $191.36 | 2022-2025 | Quviviq, Quviviq |
| Tolmar, INC. | $162.31 | 2023-2025 | Jatenzo |
| Agile Therapeutics, INC. | $154.86 | 2021-2022 | |
| Exeltis, USA INC. | $148.98 | 2021-2023 | Slynd |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $144.58 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $105.78 | 2023-2025 | Shingrix, Arexvy |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $104.33 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Therapeuticsmd, INC. | $96.97 | 2021-2022 | |
| Axsome Therapeutics, INC. | $95.68 | 2022-2025 | Auvelity |
| Sumitomo Pharma America, INC. | $85.17 | 2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $81.64 | 2024-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.74 | 2023-2025 | Jardiance, Synjardy |
| Paratek Pharmaceuticals, INC. | $76.97 | 2024 | Nuzyra |
| Ibsa Pharma INC. | $75.10 | 2024 | Tirosint, Licart, Flector |
| Antares Pharma, INC. | $71.40 | 2024-2025 | Xyosted |
| Intra-Sana Laboratories | $68.76 | 2024-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Astellas Pharma US INC | $68.19 | 2023-2024 | Veozah |
| Organon LLC | $65.93 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $59.01 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.49 | 2025 | Xifaxan |
| Mission Pharmacal Company | $28.76 | 2021 | |
| Amneal Pharmaceuticals LLC | $28.34 | 2023-2025 | Unithroid |
| Janssen Pharmaceuticals, INC | $19.53 | 2025 | Spravato |
| Hologic Sales and Service, LLC | $16.86 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.50 | 2023 | |
| Currax Pharmaceuticals LLC | $14.59 | 2023 | Contrave |
| Millicent US INC | $14.53 | 2021 | |
| Myovant Sciences INC. | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Mclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.